AR067639A1 - Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente - Google Patents
Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipienteInfo
- Publication number
- AR067639A1 AR067639A1 ARP080103160A ARP080103160A AR067639A1 AR 067639 A1 AR067639 A1 AR 067639A1 AR P080103160 A ARP080103160 A AR P080103160A AR P080103160 A ARP080103160 A AR P080103160A AR 067639 A1 AR067639 A1 AR 067639A1
- Authority
- AR
- Argentina
- Prior art keywords
- well
- excipient
- lactose
- tiotropy
- salmetrol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Preparaciones estables pulverulentas para la inhalacion, que contienen una sal de liotropio y xinafoato de salrneterol, a procedimientos para su preparacion así como su uso para la preparacion de un medicamento para el tratamiento de las vías aéreas, en especial para el tratamiento de EPOC (chronic obstructive pulmonary disease = enfermedad pulmonar obstructiva cronica) y asma. Reivindicacion 1: Polvos inhalables que contienen el excipiente lactosa, una sal por adicion de ácidos de salmeterol 2 y una sal de tiotropio 1, caracterizados porque presentan un valor aw de entre 0,05 y 0,5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007034157 | 2007-07-21 | ||
US5193308P | 2008-05-09 | 2008-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067639A1 true AR067639A1 (es) | 2009-10-21 |
Family
ID=39869109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103160A AR067639A1 (es) | 2007-07-21 | 2008-07-21 | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100189780A1 (es) |
EP (1) | EP2182933B1 (es) |
JP (1) | JP2011509919A (es) |
AR (1) | AR067639A1 (es) |
CA (1) | CA2694479C (es) |
PE (1) | PE20090907A1 (es) |
TW (1) | TW200909004A (es) |
UY (1) | UY31235A1 (es) |
WO (1) | WO2009013244A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100638936B1 (ko) * | 2005-03-31 | 2006-10-25 | 엘지전자 주식회사 | 건조기의 캐비닛 구조 |
DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
DK2277799T3 (da) * | 2009-07-23 | 2012-05-21 | Airsec Sas | Hydreret fugtighedsbekæmpelsesstof og fremgangsmåde til fremstilling deraf |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
MD4117C1 (ro) * | 2010-07-30 | 2012-02-29 | Институт Химии Академии Наук Молдовы | Pudră cu capacitate hemostatică şi regenerativă (variante) şi procedeu de obţinere a acesteia |
ES2546422T5 (es) | 2010-08-31 | 2023-01-20 | Glaxosmithkline Ip Dev Ltd | Productos medicinales de inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos |
ES2705494T3 (es) | 2010-08-31 | 2019-03-25 | Glaxosmithkline Ip Dev Ltd | Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos |
GB201113662D0 (en) | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
ITMI20120092A1 (it) * | 2012-01-26 | 2013-07-27 | Micro Macinazione S A | Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia |
WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
US8545878B1 (en) | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
BR112015013628A2 (pt) | 2012-12-18 | 2017-07-11 | Almirall Sa | derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
EA201790833A1 (ru) * | 2014-10-16 | 2017-09-29 | Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. | Сухой порошкоообразный состав |
KR101748796B1 (ko) * | 2015-09-30 | 2017-06-19 | 한미약품 주식회사 | 활성성분의 전달량이 향상된 흡입용 캡슐제 |
CA169756S (en) | 2016-02-08 | 2017-09-01 | Nicoventures Holdings Ltd | Electronic cigarette |
GB201605100D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision system |
GB201605102D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Mechanical connector for electronic vapour provision system |
GB201605101D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Electronic vapour provision system |
GB201605105D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision apparatus |
WO2018015712A1 (en) | 2016-07-22 | 2018-01-25 | Nicoventures Holdings Limited | Case for a vapour provision device |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE516555C2 (sv) * | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
JP3691459B2 (ja) * | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
DE10351663A1 (de) * | 2002-12-20 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat |
GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
-
2008
- 2008-07-17 PE PE2008001219A patent/PE20090907A1/es not_active Application Discontinuation
- 2008-07-17 UY UY31235A patent/UY31235A1/es not_active Application Discontinuation
- 2008-07-18 WO PCT/EP2008/059465 patent/WO2009013244A1/de active Application Filing
- 2008-07-18 TW TW097127515A patent/TW200909004A/zh unknown
- 2008-07-18 US US12/670,001 patent/US20100189780A1/en not_active Abandoned
- 2008-07-18 EP EP08786245.4A patent/EP2182933B1/de active Active
- 2008-07-18 CA CA2694479A patent/CA2694479C/en not_active Expired - Fee Related
- 2008-07-18 JP JP2010517374A patent/JP2011509919A/ja active Pending
- 2008-07-21 AR ARP080103160A patent/AR067639A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2694479A1 (en) | 2009-01-29 |
CA2694479C (en) | 2016-09-13 |
EP2182933A1 (de) | 2010-05-12 |
US20100189780A1 (en) | 2010-07-29 |
TW200909004A (en) | 2009-03-01 |
JP2011509919A (ja) | 2011-03-31 |
EP2182933B1 (de) | 2016-09-07 |
PE20090907A1 (es) | 2009-08-05 |
WO2009013244A1 (de) | 2009-01-29 |
UY31235A1 (es) | 2009-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
ECSP055855A (es) | Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato | |
UY26959A1 (es) | Nuevos polvos para inhalación que contienen tiotropio | |
WO2013021199A3 (en) | Eutectic mixture for pulmonary administration | |
PE20160853A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) | |
WO2009112273A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
WO2009112274A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
ECSP066544A (es) | Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen | |
DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
EP2682108A3 (en) | Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
CO6361899A2 (es) | Pariculas inhalables que comprenden tiotropio | |
NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
EP2682097A3 (en) | Dry Powder Inhalers Comprising A Carrier Other Than Lactose | |
ECSP055821A (es) | Nueva formulacion pulverulenta que contiene tiotropio destinado a la inhalación | |
BR112014005538A2 (pt) | composições aquosas compreendendo arbecacina | |
WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
WO2015049519A3 (en) | Method and apparatus for making compositions for pulmonary administration | |
UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
WO2019098969A3 (en) | Dry powder compositions for inhalation | |
MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
TH147031A (th) | ขนาดการให้ยาและสูตรผสมชนิดใหม่ | |
CL2008002135A1 (es) | Polvos inhalables que contienen el excipiente lactosa, una sal de adicion de salmeterol y una sal de tiotropio que presenta un valor de aw de entre 0,05 y 0,5; composicion farmaceutica que lo comprende; procedimiento de preparacion de dichos polvos; kit de inhalacion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |